touchMEETING HIGHLIGHTS Quad Pro Quo: Deciphering the role of anti-CD38 quadruplets in newly diagnosed multiple myeloma (NDMM)
Highlights from a sponsored symposium at the European Hematology Association (EHA) 2023 Congress considering the role of anti-CD38-KRd quadruplets in NDMM.
Symposium Chair, Dr Katja Weisel provides an overview of the agenda.
Dr Roberto Mina presents data on the efficacy and safety of KRd-based anti-CD38 monoclonal antibody quadruplets in patients with NDMM.
Dr Roberto Mina and the panel discuss a case study of a patient with NDMM receiving a KRd-based regimen.
Dr Katja Weisel outlines the role of KRd-based anti-CD38 monoclonal antibody quadruplets in patients with high-risk NDMM.
The panel discusses the use of a KRd-based regimen in patients with high-risk NDMM.
Dr Elizabeth O’Donnell presents data on the role of KRd-based anti-CD38 monoclonal antibody quadruplets irrespective of cytogenetic status.
The panel answers questions on the future of NDMM therapy including the use of quadruplets.
Overview & Learning Objectives
Overview
Highlights from a Sanofi-sponsored satellite symposium at the European Hematology Association (EHA) 2023 Congress, in which a panel of experts debate the role of anti-CD38-based quadruplet therapy in NDMM. Several completed and ongoing studies in NDMM have assessed efficacy of anti-CD38 monoclonal antibodies partnered with carfilzomib, lenalidomide and dexamethasone (KRd), in high-risk and all-risk cohorts.1-4 The panel considers the implications of these studies for clinical practice.
Learning Objectives
After watching this activity, participants should be better able to:
- Recognize that anti-CD38 mAb-based quadruplets are now standard of care for transplant-eligible NDMM.
- Recall data with anti-CD38-KRd quadruplets for high-risk and all-risk patients with NDMM.
- Discuss the role of anti-CD38-KRd quadruplets as a frontline treatment option for patients, regardless of their cytogenetic risk.
Faculty & Disclosures
Prof. Katja Weisel
University Medical Center Hamburg-Eppendorf, Germany
Katja Weisel, MD, is Deputy Director and professor of Hematology/Oncology in the Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Her research interests focus on treatment optimization for patients with high-risk multiple myeloma.
Dr Weisel discloses: Honoraria from: Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, BMS/Celgene, BeiGene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, and Takeda. Consultancy fees from: Abbvie, Amgen, Adaptive Biotech, BMS/Celgene, BeiGene, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda. Research support from: Abbvie, Amgen, BMS/Celgene, Janssen, GSK, and Sanofi.
Dr Roberto Mina
University of Turin, Italy
Roberto Mina, MD, is Assistant Professor in the Section of Hematology, Department of Medical Science, University of Turin, Italy. His research focuses on the clinical and experimental treatment of multiple myeloma and associated disorders.
Dr Mina discloses:Â Honoraria from: Sanofi, Janssen. Abbvie, Amgen, BMS, and Menarini. Advisory fees from: BMS, Janssen, Pfizer, and Sanofi.
Dr Elizabeth O’Donnell
Dana-Farber Cancer Institute, Boston, US
Elizabeth O’Donnell, MD, is the Director of Early Detection and Prevention at Dana-Farber and an Assistant Professor of Medicine at Harvard Medical School. She specializes in plasma cell disorders with a particular interest in lifestyle medicine and patient and caregiver quality of life.
Dr O’Donnell discloses: Honoraria from: BMS, Sanofi, and Janssen. Advisory fees from: BMS, and Janssen. Consultancy fees from: Takeda.Travel support from: Sanofi.
References
- Leypoldt LB, Besemer B, Asemissen AM, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36(3):885-888.
- Touzeau C, Perrot A, Hulin C, et al. Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04. J Clin Oncol. 40, 2022 (suppl 16; abstr 8002).
- Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.J Clin Oncol. 2022;40(25):2901-12.
- Landgren O, Hultcrantz M, Diamond B, et al. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. JAMA Oncol. 2021;7:862–8.
